PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
37.07%
R&D growth above 10% signals aggressive investment. Seth Klarman would demand evidence of future payoff potential.
-49.28%
Negative G&A growth (overhead reduction) needs verification. Benjamin Graham would examine impact on operations.
No Data
No Data available this quarter, please select a different quarter.
3.11%
Other expenses growth 0-10% reflects moderate increase. Benjamin Graham would investigate nature of expenses.
2.64%
Operating expenses growth 0-5% reflects moderate increase. Benjamin Graham would check revenue alignment.
2.64%
Total costs growth 0-3% reflects moderate increase. Benjamin Graham would check revenue alignment.
-60.43%
Negative interest expense growth needs verification. Benjamin Graham would examine debt reduction strategy.
3.11%
D&A growth 0-5% reflects moderate asset expansion. Benjamin Graham would check if growth drives future value.
0.38%
EBITDA growth 0-4% indicates modest gains. Howard Marks would investigate growth potential.
No Data
No Data available this quarter, please select a different quarter.
-2.64%
Negative operating income growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
70.91%
Other expenses growth above 30% signals concerning expansion. Seth Klarman would scrutinize unusual items.
0.38%
Pre-tax income growth 0-4% indicates modest gains. Howard Marks would investigate growth potential.
No Data
No Data available this quarter, please select a different quarter.
-60.43%
Negative tax expense growth needs verification. Benjamin Graham would examine sustainability.
0.38%
Net income growth 0-4% indicates modest gains. Howard Marks would investigate growth potential.
No Data
No Data available this quarter, please select a different quarter.
3.04%
EPS growth 0-4% indicates modest gains. Howard Marks would investigate growth potential.
3.04%
Diluted EPS growth 0-4% indicates modest gains. Howard Marks would investigate growth potential.
2.54%
Share increase above 2% signals significant dilution. Seth Klarman would demand explanation.
2.54%
Diluted share increase above 2% signals significant dilution. Seth Klarman would demand explanation.